GB201603568D0 - Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer - Google Patents

Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer

Info

Publication number
GB201603568D0
GB201603568D0 GBGB1603568.5A GB201603568A GB201603568D0 GB 201603568 D0 GB201603568 D0 GB 201603568D0 GB 201603568 A GB201603568 A GB 201603568A GB 201603568 D0 GB201603568 D0 GB 201603568D0
Authority
GB
United Kingdom
Prior art keywords
peptide
combination
bladder cancer
cell based
urinary bladder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1603568.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1603568.5A priority Critical patent/GB201603568D0/en
Publication of GB201603568D0 publication Critical patent/GB201603568D0/en
Priority to CR20210034A priority patent/CR20210034A/es
Priority to AU2017227967A priority patent/AU2017227967B2/en
Priority to MA054832A priority patent/MA54832A/fr
Priority to US15/445,461 priority patent/US10400011B2/en
Priority to JP2018543337A priority patent/JP2019516663A/ja
Priority to BR112018016734A priority patent/BR112018016734A2/pt
Priority to IL261266A priority patent/IL261266B2/en
Priority to MA043690A priority patent/MA43690A/fr
Priority to CR20210035A priority patent/CR20210035A/es
Priority to CA3014848A priority patent/CA3014848A1/fr
Priority to EP21171324.3A priority patent/EP3915577A1/fr
Priority to PCT/EP2017/054559 priority patent/WO2017148888A1/fr
Priority to CR20210033A priority patent/CR20210033A/es
Priority to SG10202008107QA priority patent/SG10202008107QA/en
Priority to SG10202110228Y priority patent/SG10202110228YA/en
Priority to CN202211593287.4A priority patent/CN116375797A/zh
Priority to EP17707843.3A priority patent/EP3423085A1/fr
Priority to MX2018010167A priority patent/MX2018010167A/es
Priority to KR1020187027578A priority patent/KR20180118702A/ko
Priority to SG11201806951TA priority patent/SG11201806951TA/en
Priority to CN201780014493.6A priority patent/CN109152825A/zh
Priority to IL302705A priority patent/IL302705A/en
Priority to MA43090A priority patent/MA43090A1/fr
Priority to EA201891670A priority patent/EA201891670A1/ru
Priority to CR20180398A priority patent/CR20180398A/es
Priority to TW106106638A priority patent/TWI641617B/zh
Priority to PH12018501723A priority patent/PH12018501723A1/en
Priority to CL2018002360A priority patent/CL2018002360A1/es
Priority to CONC2018/0008763A priority patent/CO2018008763A2/es
Priority to ZA2018/05838A priority patent/ZA201805838B/en
Priority to US16/457,012 priority patent/US20190330274A1/en
Priority to US16/671,994 priority patent/US20200055899A1/en
Priority to US16/671,981 priority patent/US11673917B2/en
Priority to CL2020001565A priority patent/CL2020001565A1/es
Priority to CL2020001563A priority patent/CL2020001563A1/es
Priority to US16/915,354 priority patent/US11180532B2/en
Priority to CL2021000177A priority patent/CL2021000177A1/es
Priority to JP2021086571A priority patent/JP7201740B2/ja
Priority to US17/333,945 priority patent/US20210292365A1/en
Priority to US17/339,157 priority patent/US20210292367A1/en
Priority to AU2021204201A priority patent/AU2021204201B2/en
Priority to US17/832,246 priority patent/US20220363717A1/en
Priority to JP2022206084A priority patent/JP2023033324A/ja
Priority to CL2023001324A priority patent/CL2023001324A1/es
Priority to US18/345,700 priority patent/US20240083947A1/en
Priority to AU2023204323A priority patent/AU2023204323A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/836—Intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
GBGB1603568.5A 2016-03-01 2016-03-01 Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer Ceased GB201603568D0 (en)

Priority Applications (47)

Application Number Priority Date Filing Date Title
GBGB1603568.5A GB201603568D0 (en) 2016-03-01 2016-03-01 Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
CR20210034A CR20210034A (es) 2016-03-01 2017-02-28 PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y CÉLULAS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE VEJIGA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0398)
AU2017227967A AU2017227967B2 (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
MA054832A MA54832A (fr) 2016-03-01 2017-02-28 Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
US15/445,461 US10400011B2 (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
JP2018543337A JP2019516663A (ja) 2016-03-01 2017-02-28 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤
BR112018016734A BR112018016734A2 (pt) 2016-03-01 2017-02-28 peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres
IL261266A IL261266B2 (en) 2016-03-01 2017-02-28 Peptides, combination of peptides and drug-based cells for use in immunotherapy against bladder cancer and other types of cancer
MA043690A MA43690A (fr) 2016-03-01 2017-02-28 Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
CR20210035A CR20210035A (es) 2016-03-01 2017-02-28 PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y CÉLULAS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE VEJIGA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0398)
CA3014848A CA3014848A1 (fr) 2016-03-01 2017-02-28 Peptides, combinaison de peptides et medicaments a base de cellules destines a etre utilises en immunotherapie contre le cancer de la vessie et d'autres cancers
EP21171324.3A EP3915577A1 (fr) 2016-03-01 2017-02-28 Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
PCT/EP2017/054559 WO2017148888A1 (fr) 2016-03-01 2017-02-28 Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
CR20210033A CR20210033A (es) 2016-03-01 2017-02-28 PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y CÉLULAS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE VEJIGA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0398)
SG10202008107QA SG10202008107QA (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
SG10202110228Y SG10202110228YA (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CN202211593287.4A CN116375797A (zh) 2016-03-01 2017-02-28 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
EP17707843.3A EP3423085A1 (fr) 2016-03-01 2017-02-28 Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
MX2018010167A MX2018010167A (es) 2016-03-01 2017-02-28 Peptidos, combinaciones de peptidos y medicamentos basados en celulas para el uso en la inmunoterapia contra el cancer de vejiga y otros tipos de cancer.
KR1020187027578A KR20180118702A (ko) 2016-03-01 2017-02-28 방광암 및 기타 암들에 대한 면역요법에서의 사용을 위한 펩티드, 펩티드의 조합 및 세포 기반 약제들
SG11201806951TA SG11201806951TA (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CN201780014493.6A CN109152825A (zh) 2016-03-01 2017-02-28 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
IL302705A IL302705A (en) 2016-03-01 2017-02-28 Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
MA43090A MA43090A1 (fr) 2016-03-01 2017-02-28 Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers
EA201891670A EA201891670A1 (ru) 2016-03-01 2017-02-28 Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака
CR20180398A CR20180398A (es) 2016-03-01 2017-02-28 Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga y otros tipos de cáncer
TW106106638A TWI641617B (zh) 2016-03-01 2017-03-01 用於膀胱癌和其它癌症免疫治療的肽、肽組合物和基於細胞的藥物
PH12018501723A PH12018501723A1 (en) 2016-03-01 2018-08-15 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CL2018002360A CL2018002360A1 (es) 2016-03-01 2018-08-17 Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer
CONC2018/0008763A CO2018008763A2 (es) 2016-03-01 2018-08-22 Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer
ZA2018/05838A ZA201805838B (en) 2016-03-01 2018-08-30 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
US16/457,012 US20190330274A1 (en) 2016-03-01 2019-06-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
US16/671,994 US20200055899A1 (en) 2016-03-01 2019-11-01 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
US16/671,981 US11673917B2 (en) 2016-03-01 2019-11-01 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CL2020001565A CL2020001565A1 (es) 2016-03-01 2020-06-11 Péptidos (seq id no. 119, seq id no. 2 a seq id no. 63, seq id no. 65 a seq id no. 118, y seq id no. 120 a seq id no. 149), combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer. (divisional solicitud 201802360)
CL2020001563A CL2020001563A1 (es) 2016-03-01 2020-06-11 Péptidos (seq id no. 64, seq id no. 2 a seq id no. 63, seq id no. 65 a seq id no. 118, y seq id no. 120 a seq id no. 149), combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer. (divisional solicitud 201802360)
US16/915,354 US11180532B2 (en) 2016-03-01 2020-06-29 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CL2021000177A CL2021000177A1 (es) 2016-03-01 2021-01-22 Péptidos, combinaciones de péptidos, células y kits para el uso en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201802360)
JP2021086571A JP7201740B2 (ja) 2016-03-01 2021-05-23 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤
US17/333,945 US20210292365A1 (en) 2016-03-01 2021-05-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
US17/339,157 US20210292367A1 (en) 2016-03-01 2021-06-04 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
AU2021204201A AU2021204201B2 (en) 2016-03-01 2021-06-22 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
US17/832,246 US20220363717A1 (en) 2016-03-01 2022-06-03 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
JP2022206084A JP2023033324A (ja) 2016-03-01 2022-12-22 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤
CL2023001324A CL2023001324A1 (es) 2016-03-01 2023-05-08 Péptidos, combinaciones, células para inmunoterapia contra cáncer de vejiga y otros cánceres
US18/345,700 US20240083947A1 (en) 2016-03-01 2023-06-30 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
AU2023204323A AU2023204323A1 (en) 2016-03-01 2023-07-05 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1603568.5A GB201603568D0 (en) 2016-03-01 2016-03-01 Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer

Publications (1)

Publication Number Publication Date
GB201603568D0 true GB201603568D0 (en) 2016-04-13

Family

ID=55807140

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1603568.5A Ceased GB201603568D0 (en) 2016-03-01 2016-03-01 Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer

Country Status (18)

Country Link
US (1) US10400011B2 (fr)
EP (2) EP3915577A1 (fr)
JP (2) JP2019516663A (fr)
KR (1) KR20180118702A (fr)
CN (1) CN109152825A (fr)
AU (2) AU2017227967B2 (fr)
BR (1) BR112018016734A2 (fr)
CA (1) CA3014848A1 (fr)
CO (1) CO2018008763A2 (fr)
CR (4) CR20210033A (fr)
EA (1) EA201891670A1 (fr)
GB (1) GB201603568D0 (fr)
IL (1) IL261266B2 (fr)
MA (2) MA43090A1 (fr)
MX (1) MX2018010167A (fr)
SG (3) SG11201806951TA (fr)
TW (1) TWI641617B (fr)
WO (1) WO2017148888A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
MX2019007924A (es) 2016-12-28 2020-01-27 Invvax Inc Vacunas contra la influenza.
EP3428194B1 (fr) 2017-07-14 2021-08-18 Immatics Biotechnologies GmbH Molécule de polypeptide à double spécificité améliorée
US11696938B2 (en) * 2017-11-21 2023-07-11 Naofumi Miwa Human cancer cell metastasis inhibitory agent and human cancer cell determination agent
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
CA3090416A1 (fr) 2018-02-09 2019-08-15 Immatics US, Inc. Procedes de fabrication de lymphocytes t
CA3097399A1 (fr) * 2018-04-19 2019-10-24 The Board Of Regents, The University Of Texas System Recepteurs de lymphocytes t specifiques de mage-b2 et leurs utilisations
CN113538407B (zh) 2018-12-29 2022-10-14 北京市商汤科技开发有限公司 锚点确定方法及装置、电子设备和存储介质
WO2020191172A1 (fr) 2019-03-19 2020-09-24 Immatics US, Inc. Cultures de cellules t cd28, leurs compositions et leurs méthodes d'utilisation
MX2021014552A (es) 2019-05-27 2022-02-11 Immatics Us Inc Vectores viricos y uso de los mismos en terapias celulares adoptivas.
WO2020245326A1 (fr) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Tri avec sélection de compteur à l'aide de peptides similaires à une séquence
US20230000960A1 (en) * 2019-06-12 2023-01-05 Biontech Us Inc. Neoantigen compositions and uses thereof
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN111118011B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0027478表达的siRNA及其应用
CN115427554A (zh) 2020-02-24 2022-12-02 伊玛提克斯美国公司 扩增t细胞治疗癌症和相关恶性肿瘤的方法
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
JP2024516699A (ja) 2021-05-05 2024-04-16 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｂｍａ０３１抗原結合ポリペプチド
WO2023025851A1 (fr) 2021-08-24 2023-03-02 Immatics US, Inc. Sélection de cellules immunitaires à l'aide de complexes peptide-cmh générés par échange de ligands conditionnel
US20230145121A1 (en) * 2021-08-31 2023-05-11 Washington University Neoantigen vaccines for triple negative breast cancer
WO2023044488A1 (fr) 2021-09-20 2023-03-23 Immatics US, Inc. Déplétion monocytaire des populations de lymphocytes t pour une thérapie par lymphocytes t
WO2023081925A1 (fr) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Traitement combiné de thérapie cellulaire adoptive et compositions associées
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212655A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
WO2023215825A1 (fr) 2022-05-05 2023-11-09 Immatics US, Inc. Procédés d'amélioration de l'efficacité d'un lymphocyte t
CN115785206B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标07及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1463928A2 (fr) * 2001-04-18 2004-10-06 Protein Design Labs Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
WO2003104429A2 (fr) 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes surexprimes par le cancer des ovaires et leur utilisation dans la mise au point de nouvelles therapies
EP1806359B1 (fr) * 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Peptides associeés a des tumeurs et se liantes a des différentes antigènes d'histocompatibilité (HLA) de classe II
KR100906145B1 (ko) * 2006-05-30 2009-07-03 한국생명공학연구원 Ｔｍｐｒｓｓ4 억제제를 유효성분으로 포함하는 항암제
KR20150033726A (ko) * 2006-07-05 2015-04-01 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
SI2172211T1 (sl) * 2008-10-01 2015-03-31 Immatics Biotechnologies Gmbh Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
EP2336771A1 (fr) * 2009-12-16 2011-06-22 Universität Duisburg-Essen HAS3v2 en tant que marqueur de tumeur
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201511792D0 (en) * 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers

Also Published As

Publication number Publication date
US10400011B2 (en) 2019-09-03
MX2018010167A (es) 2018-11-29
AU2017227967B2 (en) 2021-03-25
SG10202008107QA (en) 2020-09-29
JP2021129580A (ja) 2021-09-09
CR20210033A (es) 2021-02-10
JP2019516663A (ja) 2019-06-20
CR20210034A (es) 2021-02-10
SG10202110228YA (en) 2021-10-28
AU2021204201B2 (en) 2023-04-13
TWI641617B (zh) 2018-11-21
IL261266B2 (en) 2023-10-01
BR112018016734A2 (pt) 2018-12-26
CR20180398A (es) 2018-11-30
CR20210035A (es) 2021-02-10
WO2017148888A1 (fr) 2017-09-08
EA201891670A1 (ru) 2019-02-28
US20170253633A1 (en) 2017-09-07
AU2017227967A1 (en) 2018-09-06
CA3014848A1 (fr) 2017-09-08
IL261266B1 (en) 2023-06-01
TW201734039A (zh) 2017-10-01
JP7201740B2 (ja) 2023-01-10
MA43690A (fr) 2021-06-02
AU2021204201A1 (en) 2021-07-15
SG11201806951TA (en) 2018-09-27
IL261266A (en) 2018-10-31
CO2018008763A2 (es) 2018-08-31
EP3423085A1 (fr) 2019-01-09
EP3915577A1 (fr) 2021-12-01
CN109152825A (zh) 2019-01-04
KR20180118702A (ko) 2018-10-31
MA43090A1 (fr) 2018-10-31

Similar Documents

Publication Publication Date Title
GB201603568D0 (en) Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
HRP20210709T8 (hr) Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
SG11201801344SA (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
SG11201706681VA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
LT3430027T (lt) Peptidas, skirtas panaudoti imunoterapijoje prieš nesmulkialąstelinį plaučių vėžį ir smulkialąstelinį plaučių vėžį
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
IL261786A (en) Peptides and a combination of peptides for use in immunotherapy against types of cancer
ZA201704726B (en) Peptides and their use in the treatment of skin
HK1246181A1 (zh) 用於各種腫瘤免疫治療的新型肽和肽組合物
HK1245096A1 (zh) 用於癌症治療的細胞治療劑以及使用該細胞治療劑的聯合治療
HK1185808A1 (zh) 用於治療癌症的包含威羅菲尼和干擾素的組合療法
ZA201805838B (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
EP3380112A4 (fr) Peptides et leur utilisation dans le traitement de la peau
HK1258386A1 (zh) 用於小細胞肺癌和其他癌症免疫治療的肽和肽組合物
IL262081A (en) New peptides and combinations of peptides for use in immunotherapy for the treatment of acute myeloid leukemia and other cancers
ZA202001435B (en) Abx196 for use in the treatment of bladder cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)